FDA Approved Ultrasound System for Prostate Cancer Treatment

bph_cancer treatment

The U.S. Food and Drug Administration (FDA) has approved SonaCare Medical’s Sonablate 450 focused ultrasound system for ablation therapy on prostate tissue. A pioneer in high intensity focused ultrasound (HIFU) technologies, the Indianapolis, Indiana based SonaCare reports that it has received de novo clearance from the FDA to market the Sonablate 450 in the U.S., making it the first high intensity therapeutic ultrasound (HITU) device to receive the agency’s regulatory authorization for prostate tissue ablation — a non-invasive, radiation-free technique used to treat localized prostate cancer. SonaCare Medical expects to begin U.S. distribution this month.

Read more about it: http://bit.ly/1orufR1

Tagged , , , .

Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.

Leave a Comment

Your email address will not be published. Required fields are marked *